Insider Buying: Amicus Therapeutics, Inc. (FOLD) Major Shareholder Buys 50,000 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) major shareholder Life Sciences Maste Perceptive bought 50,000 shares of the stock in a transaction dated Wednesday, October 3rd. The stock was purchased at an average cost of $12.59 per share, for a total transaction of $629,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Friday, September 21st, Life Sciences Maste Perceptive bought 50,000 shares of Amicus Therapeutics stock. The stock was purchased at an average cost of $12.53 per share, for a total transaction of $626,500.00.
  • On Wednesday, September 12th, Life Sciences Maste Perceptive bought 500,000 shares of Amicus Therapeutics stock. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $6,000,000.00.

Shares of NASDAQ FOLD opened at $13.44 on Monday. The stock has a market capitalization of $2.29 billion, a PE ratio of -4.60 and a beta of 1.33. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.73 and a current ratio of 10.88. Amicus Therapeutics, Inc. has a 1 year low of $11.57 and a 1 year high of $17.62.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). The company had revenue of $21.31 million for the quarter, compared to analyst estimates of $18.92 million. Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. Analysts expect that Amicus Therapeutics, Inc. will post -1.19 EPS for the current year.

A number of equities research analysts have commented on FOLD shares. ValuEngine lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 19th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Tuesday, July 10th. Chardan Capital lowered shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $18.00 to $15.00 in a report on Friday, August 17th. Finally, BidaskClub raised shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $19.80.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Xact Kapitalforvaltning AB boosted its stake in shares of Amicus Therapeutics by 14.0% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 29,241 shares of the biopharmaceutical company’s stock valued at $457,000 after purchasing an additional 3,600 shares during the last quarter. Strs Ohio boosted its stake in shares of Amicus Therapeutics by 32.2% in the 2nd quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 3,900 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Amicus Therapeutics by 16.1% in the 2nd quarter. Amalgamated Bank now owns 28,896 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 4,011 shares during the last quarter. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Amicus Therapeutics by 14.0% in the 2nd quarter. Berson & Corrado Investment Advisors LLC now owns 36,870 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 4,514 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Amicus Therapeutics by 14.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 39,810 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 4,923 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply